Current Liabilities decreased faster than Ortho Clinical Diagnostics Holdings Plc's Cash & cash equivalent, this led to improvement in Ortho Clinical Diagnostics Holdings Plc's Quick Ratio to 0.54 a new company high.

Within In Vitro & In Vivo Diagnostic Substances industry 19 other companies have achieved higher Quick Ratio than Ortho Clinical Diagnostics Holdings Plc in first quarter 2022. While Quick Ratio total ranking in the first quarter 2022 has deteriorated compared to the prior quarter from 3477 to 3489.

Explain Quick Ratio?
How much Cash & cash equivalents OCDX�s has?
What are OCDX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

OCDX Quick Ratio	(Apr 03 2022) Q1	(Jan 02 2022) Q4	(Oct 03 2021) Q3	(Jul 04 2021) Q2	(Apr 04 2021) Q1
Y / Y Current Liabilities Change	-7.47 %	-5.3 %	-	-	-
Y / Y Cash & cash equivalent Change	82.77 %	118.25 %	-	-	-
Quick Ratio MRQ	0.54	0.51	0.52	0.42	0.27
OCDX's Total Ranking	# 3489	# 3477	# 1847	# 3370	# 0
Seq. Current Liabilities Change	-14.13 %	24.78 %	1.79 %	-15.17 %	-12.12 %
Seq. Cash & cash equivalent Change	-9.23 %	21.02 %	27.38 %	30.62 %	8.39 %

Quick Ratio first quarter 2022 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 20
Healthcare Sector	# 1055
Overall Market	# 3489

Quick Ratio Statistics
High	Average	Low
0.54	0.46	0.27
(Apr 03 2022)		(Apr 04 2021)

Financial Statements
Ortho Clinical Diagnostics Holdings Plc's Current Liabilities	$ 523 Millions	Visit OCDX's Balance sheet
Ortho Clinical Diagnostics Holdings Plc's Cash & cash equivalent	$ 281 Millions	Visit OCDX's Balance sheet
Source of OCDX's Sales		Visit OCDX's Sales by Geography

Cumulative Ortho Clinical Diagnostics Holdings Plc's Quick Ratio

OCDX's Quick Ratio for the trailling 12 Months

OCDX Quick Ratio	(Apr 03 2022) 12 Months	(Jan 02 2022) 12 Months	(Oct 03 2021) 12 Months	(Jul 04 2021) 12 Months	(Apr 04 2021) 12 Months
Y / Y Current Liabilities TTM Growth	73.75 %	233.01 %	-	-	-
Y / Y Cash & cash equivalent TTM Growth	254.28 %	548.56 %	-	-	-
Quick Ratio TTM	0.5	0.43	0.35	0.29	0.24
Total Ranking TTM	# 3358	# 2317	# 0	# 0	# 0
Seq. Current Liabilities TTM Growth	-1.97 %	-1.57 %	28.92 %	39.68 %	87.88 %
Seq. Cash & cash equivalent TTM Growth	13.83 %	22.3 %	51.53 %	67.94 %	108.39 %

Quick ratio ranking by company, industry and sector >> Back to OCDX Financial Strength Comparisons >> Go to Compare OCDX Quick Ratio to its Competitors

On the trailing twelve months basis OCDX Cash & cash equivalent soared by 82.77 % in Q1 2022 year on year, while Current Liabilities fell to $523 millions, this led to increase in in Ortho Clinical Diagnostics Holdings Plc's Quick Ratio to 0.5, above OCDX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 18 other companies have achieved higher Quick Ratio than Ortho Clinical Diagnostics Holdings Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2021 from 2317 to 3358.

Explain Quick Ratio?
How much Cash & cash equivalents OCDX�s has?
What are OCDX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 19
Healthcare Sector	# 1039
Within the Market	# 3358

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.51	0.47	0.44
(Apr 03 2022)		(Jan 02 2022)

Companies with similar Quick Ratio in the quarter ending Apr 03 2022, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Apr 03 2022 MRQ Cash & cash equivalent	Apr 03 2022 MRQ Current Liabilities
Insight Molecular Diagnostics Inc	1.46	$ 20.412 Millions	$ 13.955 Millions
Volitionrx Limited	1.36	$ 23.732 Millions	$ 17.513 Millions
Meridian Bioscience Inc	1.35	$ 76.487 Millions	$ 56.465 Millions
Nymox Pharmaceutical Corporation	0.98	$ 2.075 Millions	$ 2.107 Millions
Burzynski Research Institute Inc	0.97	$ 0.003 Millions	$ 0.004 Millions
Lantheus Holdings Inc	0.59	$ 105.355 Millions	$ 177.657 Millions
Ortho Clinical Diagnostics Holdings Plc	0.54	$ 281.100 Millions	$ 522.700 Millions
Trinity Biotech Plc	0.49	$ 8.412 Millions	$ 17.339 Millions
Quotient Limited	0.25	$ 67.685 Millions	$ 270.745 Millions
Navidea Biopharmaceuticals Inc	0.25	$ 1.217 Millions	$ 4.900 Millions
Idexx Laboratories Inc	0.22	$ 204.618 Millions	$ 930.436 Millions

Date modified: 2026-09-08T15:10:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.